MediPharm Labs Past Earnings Performance

Past criteria checks 0/6

MediPharm Labs's earnings have been declining at an average annual rate of -22.4%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been declining at an average rate of 19.9% per year.

Key information

-22.4%

Earnings growth rate

-6.7%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate-19.9%
Return on equity-28.5%
Net Margin-53.2%
Next Earnings Update27 Mar 2024

Recent past performance updates

Recent updates

Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Mar 23
Market Might Still Lack Some Conviction On MediPharm Labs Corp. (TSE:LABS) Even After 31% Share Price Boost

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Jan 10
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

Sep 06
MediPharm Labs (TSE:LABS) Has Debt But No Earnings; Should You Worry?

MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 17
MediPharm Labs Corp. (TSE:LABS) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Aug 20
Time To Worry? Analysts Just Downgraded Their MediPharm Labs Corp. (TSE:LABS) Outlook

Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

May 21
Some Analysts Just Cut Their MediPharm Labs Corp. (TSE:LABS) Estimates

Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Apr 06
Things Look Grim For MediPharm Labs Corp. (TSE:LABS) After Today's Downgrade

Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Mar 07
Is MediPharm Labs (TSE:LABS) Using Too Much Debt?

Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Aug 18
Does MediPharm Labs (TSE:LABS) Have A Healthy Balance Sheet?

Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

May 23
Some MediPharm Labs Corp. (TSE:LABS) Analysts Just Made A Major Cut To Next Year's Estimates

Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Jan 11
Reflecting on MediPharm Labs' (TSE:LABS) Share Price Returns Over The Last Year

Revenue & Expenses Breakdown
Beta

How MediPharm Labs makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSX:LABS Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2330-16230
30 Jun 2328-19221
31 Mar 2323-26211
31 Dec 2222-30241
30 Sep 2222-46322
30 Jun 2220-46322
31 Mar 2221-48321
31 Dec 2122-55312
30 Sep 2122-64222
30 Jun 2122-72231
31 Mar 2130-63252
31 Dec 2036-66282
30 Sep 2062-39352
30 Jun 20101-20352
31 Mar 20118-15332
31 Dec 191292311
30 Sep 191071220
30 Jun 1964-4170
31 Mar 1932-8120
31 Dec 1810-860
30 Sep 180-640
30 Jun 180-430
31 Mar 180-220
31 Dec 170-110

Quality Earnings: LABS is currently unprofitable.

Growing Profit Margin: LABS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LABS is unprofitable, and losses have increased over the past 5 years at a rate of 22.4% per year.

Accelerating Growth: Unable to compare LABS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LABS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (100.1%).


Return on Equity

High ROE: LABS has a negative Return on Equity (-28.49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.